Goldman Initiates Dendreon At Buy, $50 PT

Goldman Sachs has initiated coverage on Dendreon Corporation DNDN with a Buy rating and $50 price target.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Price TargetInitiationAnalyst RatingsBiotechnologyDendreonGoldman SachsHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!